APA (7th ed.) Citation

T, P., D, G., A, W., M, S., Y, N., A, G., . . . DR, C. (2025). The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. Lung cancer (Amsterdam, Netherlands), 199, 108040. https://doi.org/10.1016/j.lungcan.2024.108040

Chicago Style (17th ed.) Citation

T, Patil, et al. "The Efficacy of Continuing Osimertinib with Platinum Pemetrexed Chemotherapy upon Progression in Patients with Metastatic Non-small Cell Lung Cancer Harboring Sensitizing EGFR Mutations." Lung Cancer (Amsterdam, Netherlands) 199 (2025): 108040. https://doi.org/10.1016/j.lungcan.2024.108040.

MLA (9th ed.) Citation

T, Patil, et al. "The Efficacy of Continuing Osimertinib with Platinum Pemetrexed Chemotherapy upon Progression in Patients with Metastatic Non-small Cell Lung Cancer Harboring Sensitizing EGFR Mutations." Lung Cancer (Amsterdam, Netherlands), vol. 199, 2025, p. 108040, https://doi.org/10.1016/j.lungcan.2024.108040.